Core B, the Antibody / Ig Fusion Core, will coordinate the use of mAb and Ig fusion proteins for the study of the roles of pathways in the B7:CD28 superfamily in regulating T cell activation and tolerance in vivo, so that these reagents are an easily accessible means of addressing the functions of these important immunoregulatory pathways in vivo. Core B will serve as a critical means by which the Costimulation PPG will achieve its goals of understanding the in vivo functions of the negative second signals provided by pathways in the B7:CD28 family individually, the interactions among these negative signals, and the balance between stimulatory and inhibitory signals transmitted by pathways within the B7:CD28 superfamily. The major goals of Core B, the Antibody / Ig Fusion Core, are to generate novel reagents that facilitate the analysis of the expression and function of B7:CD28 family members and to serve as a repository for and provide existing reagents for the Costimulation PPG Projects and Core C. The generation of novel reagents that induce negative signals is central to the mission of the Costimulation PPG, and Core B provides a critical means by which the PPG will achieve this goal. The availability of large quantities of Ig fusion proteins and mAbs is critical to the success of Projects 1-5. Ig fusion proteins will be used for expression, functional, and signaling studies. Ig fusion proteins, via binding to their ligand, will visualize ligand-expressing cells and may act as agonists via cross-linking and transducing signals through receptors. In addition, Ig fusion proteins may serve as a means to specifically block receptor/ligand interactions. MAbs also will be used to visualize the expression of B7:CD28 family members and as pathway agonists and antagonists. To accomplish these goals, Core B has two aims:
Specific Aim 1 : To generate novel monoclonal antibodies to study the function and expression of B7:CD28 family members and their polymorphic variants.
Specific Aim 2 : To serve as a repository and maintain and produce existing and newly generated mAbs and Ig fusion proteins for PPG investigators. The production of these critical reagents by a core not only will be time and cost efficient, but also provide standardized reagents that will facilitate comparison of data by investigators in this PPG.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI056299-10
Application #
8712939
Study Section
Special Emphasis Panel (ZAI1-RJ-I (J1))
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$291,014
Indirect Cost
$47,441
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Xu, Jie; Sun, Heather H; Fletcher, Christopher D M et al. (2016) Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol 40:443-53
Borges, Christopher M; Reichenbach, Dawn K; Kim, Beom Seok et al. (2016) Regulatory T cell expressed MyD88 is critical for prolongation of allograft survival. Transpl Int 29:930-40
Chapuy, Bjoern; Roemer, Margaretha G M; Stewart, Chip et al. (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869-81
Schildberg, Frank A; Klein, Sarah R; Freeman, Gordon J et al. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:955-72
Schönle, Anne; Hartl, Frederike A; Mentzel, Jan et al. (2016) Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. Blood 127:1930-9
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Zeiser, Robert; Blazar, Bruce R (2016) Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood 127:3117-26
Hirakawa, Masahiro; Matos, Tiago; Liu, Hongye et al. (2016) Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells. JCI Insight 1:e89278
Li, Wei; Liu, Liangyi; Gomez, Aurelie et al. (2016) Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight 1:
Lo, Tsun-Ho; Silveira, Pablo A; Fromm, Phillip D et al. (2016) Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration. J Immunol 197:885-98

Showing the most recent 10 out of 257 publications